Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients

Authors: Valencak, J.; Weihsengruber, F.; Rappersberger, K.; Trautinger, F.; Chott, A.; Streubel, B.; Muellauer, L.; Der-Petrossian, M.; Jonak, C.; Binder, M.; Raderer, M.

Source: Annals of Oncology, Volume 20, Number 2, 14 February 2009 , pp. 326-330(5)

Publisher: Oxford University Press

Buy & download fulltext article:

OR

Price: $42.29 plus tax (Refund Policy)

Abstract:

Background: We have carried out a retrospective analysis to evaluate the therapeutic value of the anti-CD20 antibody rituximab in 16 consecutive patients with primary cutaneous CD20 B-cell lymphomas.

Patients and methods: Sixteen patients (4 females, 12 males) with a median age of 54 years received systemic therapy with rituximab 375 mg/m2 once weekly for four or six consecutive weeks. Eleven patients had primary cutaneous follicle center cell lymphoma and five patients had a primary cutaneous marginal zone B-cell lymphoma.

Results: Of the 16 patients with PCBCL, 14 patients (87.5%) achieved complete remission (CR). In two patients, partial remission was obtained and additional focal radiotherapy was applied, which resulted in final CR. Five to 14 (35%) patients with CR relapsed, in an interval between 6 and 37 months. There were no severe side-effects.

Conclusions: On the basis of our results, single-agent treatment with i.v. rituximab appears to be feasible and safe and results in a high rate of durable remissions. Judging from our data, it appears to be an attractive treatment option and should be directly compared with local radiotherapy.

Keywords: cutaneous B-cell lymphoma; rituximab; systemic treatment

Document Type: Research article

DOI: http://dx.doi.org/10.1093/annonc/mdn636

Publication date: 2009-02-14

More about this publication?
  • Annals of Oncology is a multidisciplinary journal that publishes articles addressing medical oncology, surgery, radiotherapy, paediatric oncology, basic research and the comprehensive management of patients with malignant diseases.
Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page